[Achievement of deep molecular response in an elderly chronic myeloid leukemia patient intolerant to imatinib and nilotinib].

Abstract

A 90-year-old woman was diagnosed with chronic myeloid leukemia (CML) of the high risk type (Sokal score 1.5), and was administered imatinib (400 mg/day). However, imatinib had to be switched to nilotinib because she suffered persistent vomiting and nausea. Although a cytogenetic response was achieved, the nilotinib administration also had to be stopped because the patient developed QTc prolongation and heart failure. After she had recovered from heart failure, the patient was given dasatinib (50 mg/day). No non-hematological adverse events occurred and she achieved a molecular response with administration of dasatinib. A molecular response can be achieved through appropriate supportive care and careful selection of tyrosine kinase inhibitors, with adjustments in the doses of these drugs administered to patients with the high-risk form of CML who are intolerant to imatinib.

• Authors: Miwa Kurimoto, Akihisa Nagata, Naohiro Sekiguchi, Satoshi Noto, Naoki Takezako
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 56 Issue 12 Pg. 2467-71 (Dec 2015) ISSN: 0485-1439 [Print] Japan
• PMID: 26725357 (Publication Type: Case Reports, Journal Article)

Chemical References

• Pyrimidines
• Imatinib Mesylate
• nilotinib
• Dasatinib

Topics

• Aged, 80 and over
• Dasatinib (administration & dosage)
• Drug Resistance, Neoplasm (drug effects)
• Female
• Humans
• Imatinib Mesylate (administration & dosage)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (diagnosis, drug therapy)
• Pyrimidines (administration & dosage)